SILEO (dexmedetomidine oromucosal gel) is the first medication approved by the US Food and Drug Administration (FDA) for treatment of noise aversion in dogs.
Noise aversion refers to the behavioural and clinical signs of fear and anxiety experienced by dogs in response to noise.
SILEO, which is being marketed in the US by Zoetis Inc, is available from veterinarians by prescription and can be safely administered at home by pet owners to help calm dogs without sedating for the duration of noise events.
"SILEO works the way veterinarians and pet owners need it to work, calming dogs while allowing them to interact normally with the family," said Stanford.
More From This Section
"It has rapid speed of onset, is easy to administer at home and works 'in the moment,' without any other treatments or training," said Stanford.
The oromucosal gel formulation blocks norepinephrine release, a chemical in the brain that is involved with the development of fear and anxiety.
This allows dogs with noise aversion to remain calm yet fully functional. In addition, the medication has a rapid speed of onset that can be tailored to the timing and duration of noise events. It works on its own without any other treatments or training.
At least one-third of pet owners report that their dog suffers from noise aversion1. Common clinical signs include panting, trembling, cowering, and escape behaviour, which can result in self-trauma as well as property damage.
However, only 40 per cent of pet owners seek treatment from their veterinarian; 20 per cent look for solutions on their own, while the remaining 40 per cent of dogs suffering from noise aversion do not receive any treatment.